Abstract: Biocartis is a molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary Idylla™ platform, which is a fully automated sample-to-result, real-time PCR system enabling fast and effective diagnosis, disease staging, treatment selection and treatment progress monitoring. Biocartis has developed tests for diagnosing melanoma, colorectal and lung cancer, as well as various infectious diseases.
In addition, Biocartis has active partnership programs with both pharmaceutical companies, for which we develop tests for our Idylla™ platform, and diagnostic & biomarker companies, which port their tests on our Idylla™ platform.
The patented Idylla™ platform forms the basis for these collaborations. Harry Kraft, Head of IP at Biocartis, will explore IP driven business models built around the IdyllaTM platform. The talk will touch on offensive/defensive strategies and how to deal with and maintain – product – patent portfolio fit as the product and patent portfolio matures over time.
